Lates News

On Tuesday, the Lilly Company stated that its daily weight loss pill helped obese and type 2 diabetes patients lose weight in late-stage trials, meeting the main goal of the study and paving the way for the company to seek approval for the drug globally. This treatment method is gradually becoming a new needle-free alternative in the lucrative market of GLP-1s for weight loss and diabetes medications. The more convenient pill form can increase the supply of treatment and is easier to obtain compared to the expensive weekly injections that currently dominate the field. Unlike similar oral treatments from main competitor Novo Nordisk, Lilly's pill does not require dietary restrictions. In a 72-week trial, the highest dose of the oral medication orforglipron helped patients on average lose 10.5% of their weight (approximately 10.4 kilograms), while patients taking a placebo only lost 2.2%. If all patients (including dropouts) are included in the analysis, the weight loss effect of the drug is 9.6%.